Skip to main content

Biogen's head of late-stage trials leaves for Sarepta

Gilmore O’Neill’s exit from Biogen comes at a particularly inopportune moment for the company, which is testing a potential Alzheimer’s treatment in late-stage studies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.